| Title |
Combination Therapy with Thalidomide, Incadronate, and Dexamethasone for Relapsed or Refractory Multiple Myeloma
|
|---|---|
| Published in |
International Journal of Hematology, October 2005
|
| DOI | 10.1532/ijh97.05049 |
| Pubmed ID | |
| Authors |
Naoya Ochiai, Noriko Yamada, Ryo Uchida, Shin-ichi Fuchida, Akira Okano, Mayumi Hatsuse, Masashi Okamoto, Eishi Ashihara, Chihiro Shimazaki |
| Abstract |
The feasibility and efficacy of a combination of thalidomide, incadronate, and dexamethasone (TID) were studied in 12 patients with relapsed or refractory multiple myeloma. The protocol, consisting of 300 mg/day of thalidomide administered orally, intravenous incadronate (10 mg/day) administered weekly, and 12 mg/day dexamethasone for 4 days, was repeated every 3 weeks. Evaluations of efficacy and toxicity were carried out every 3 weeks and were continued for 3 cycles. Three patients were excluded during the study because of apnea, severe somnolence, and pancytopenia. Of 9 evaluated patients, the partial responses achieved in 3 patients and the minor responses achieved in 4 patients corresponded to a response rate of 78% according to the criteria of the European Group for Blood and Marrow Transplantation. In addition, painful osteolytic symptoms improved rapidly after 1 cycle of TID therapy in the 10 patients evaluated. These data suggest that TID is a feasible and promising therapeutic approach for refractory and relapsed multiple myeloma. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 50% |
| Scientists | 1 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 11 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 11 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 3 | 27% |
| Other | 2 | 18% |
| Student > Ph. D. Student | 2 | 18% |
| Student > Master | 2 | 18% |
| Student > Bachelor | 1 | 9% |
| Other | 0 | 0% |
| Unknown | 1 | 9% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 45% |
| Psychology | 3 | 27% |
| Economics, Econometrics and Finance | 1 | 9% |
| Engineering | 1 | 9% |
| Unknown | 1 | 9% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 24 May 2023.
All research outputs
#6,820,862
of 23,862,416 outputs
Outputs from International Journal of Hematology
#223
of 1,448 outputs
Outputs of similar age
#19,020
of 60,461 outputs
Outputs of similar age from International Journal of Hematology
#1
of 6 outputs
Altmetric has tracked 23,862,416 research outputs across all sources so far. This one has received more attention than most of these and is in the 70th percentile.
So far Altmetric has tracked 1,448 research outputs from this source. They receive a mean Attention Score of 4.3. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 60,461 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.
We're also able to compare this research output to 6 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them